LABORATORY RESEARCH Klf4 Transcription Factor Is Expressed in the Cytoplasm of Prostate Cancer Cells Investigators comparatively addressed the expression of genes encoding putative stemness regulators including c-Myc, Klf4, Nanog, Oct4A and Sox2 genes in benign prostatic hyperplasia and prostate cancer. [Eur J Cancer] Abstract Antioxidant Treatment Promotes Prostate Epithelial Proliferation in Nkx3.1 Mutant Mice Loss of expression of the homeobox transcription factor NKX3.1 in the prostate is frequently associated with human prostate cancer. While the mechanisms by which Nkx3.1 loss promotes prostate tumorigenicity are not completely understood, published data have suggested that elevated reactive oxygen species associated with Nkx3.1 loss may be a causative factor. The authors tested this hypothesis by treating Nkx3.1 mutant mice with the antioxidant N-acetylcysteine for 13 weeks post-weaning. [PLoS One] Full Article Quercetin Inhibits Angiogenesis Mediated Human Prostate Tumor Growth by Targeting VEGFR- 2 Regulated AKT/mTOR/P70S6K Signaling Pathways Researchers discovered that quercetin reduced the cell viability and induced apoptosis in prostate cancer cells, which were correlated with the downregulation of AKT, mTOR and P70S6K expressions. [PLoS One] Full Article Interleukin-27 Expression Modifies Prostate Cancer Cell Crosstalk with Bone and Immune Cells Prostate cancer is frequently associated with bone metastases, where the crosstalk between tumor cells and key cells of the bone microenvironment amplifies tumor growth. Scientists explored the potential of a novel cytokine, interleukin-27 (IL-27), for inhibiting this malignant crosstalk, and examined the effect of autocrine IL-27 on prostate cancer cell gene expression, as well as the effect of paracrine IL-27 on gene expression in bone and T cells. [J Cell Physiol] Abstract Vorinostat and Bortezomib Synergistically Cause Ubiquitinated Protein Accumulation in Prostate Cancer Cells Researchers investigated whether the histone deacetylase inhibitor vorinostat and the proteasome inhibitor bortezomib would synergistically cause the accumulation of ubiquitinated proteins in prostate cancer cells. [J Urol] Abstract GRP78-Targeted Nanotherapy Against Castrate-Resistant Prostate Cancer Cells Expressing Membrane GRP78 The authors developed anti-KDEL functionalized polymeric nanoparticles loaded with paclitaxel to specifically target prostate cancer cells expressing glucose-regulated protein 78 (GRP78). [Target Oncol] Abstract Serum Testosterone Plays an Important Role in the Metastatic Ability of Castration Resistant Prostate Cancer Investigators aimed to determine the role of testosterone in the formation of metastases of castration resistant prostate cancer in both in vitro and in vivo settings. [World J Urol] Abstract | Full Article Wedelolactone, a Medicinal Plant-Derived Coumestan, Induces Caspase-Dependent Apoptosis in Prostate Cancer Cells via Downregulation of Protein Kinase Cε without Inhibiting Akt Wedelolactone (WDL) is known to inhibit 5-lipoxygenase activity in neutrophils. However, its effect on apoptosis in prostate cancer cells has not been addressed. Researchers tested the effects of WDL on human prostate cancer cells in vitro. They observed that WDL kills both androgen-sensitive as well as androgen-independent prostate cancer cells in a dose-dependent manner by dramatically inducing apoptosis. [Int J Oncol] Abstract CLINICAL RESEARCH The Impact of Dose-Escalated Radiotherapy plus Androgen Deprivation for Prostate Cancer Using Two Linked Nomograms The authors designed a model to estimate the results of various doses of radiotherapy combined with various durations of androgen-deprivation therapy. [Cancer] Abstract Frequency of Brain Metastases from Prostate Cancer: An 18-Year Single-Institution Experience Researchers compared the incidence of brain metastases in the pre- and post-docetaxel era in a single institution in which all oncological patients are referred to one radiotherapy and one medical oncology department. [J Neurooncol] Full Article |